CHARLESTON, SC - QuicksortRx, a technology company helping health systems improve pharmacy purchasing and reduce medication costs, has announced that its clients have achieved over $100 million in medication cost savings through the platform since the company launched in late 2018.

Founded by pharmacists and technologists from the Medical University of South Carolina (MUSC), QuicksortRx empowers health systems to instantly assess medication price, availability, and purchasing trends across multiple facilities. By streamlining pharmaceutical market analysis, QuicksortRx clients use the business intelligence platform to drive faster, more informed decisions and to improve efficiency in medication procurement.

The $100 million figure represents realized savings tracked by health systems using QuicksortRx to identify and operationalize changes in their medication procurement. Savings are most often achieved by health system pharmacy staff acting on insights from the platform to optimize product selection, identify and correct contract issues, and target strategic 340B interventions. The platform monitors initiatives identified and executed by the health system in real time, capturing savings as they are achieved.

"Having spent my entire career before QuicksortRx at MUSC, I know the financial constraints hospitals work under," said Jonathan Yantis, CEO and Co-Founder of QuicksortRx. "There are limited resources to go around to important projects that affect lives. The impetus for QuicksortRx was to help free up capital that could be more efficiently invested in patient care. It's difficult to put into words what it means to know we have enabled non-profit health systems to redeploy over $100 million into initiatives that benefit their communities. It feels really good."

QuicksortRx began as a project when Yantis, an MUSC network engineer, teamed up with Matt Hebbard and MUSC's pharmacy department to develop software that would help the health system better manage their medication spend. In the early stages of the platform's development, the inventors envisioned a solution that could be used outside MUSC.

"We knew other pharmacy departments were struggling with this work just like we were," said Hebbard, Vice President of Pharmacy and Co-Founder of QuicksortRx. "From the outset, Jonathan had the mentality that we could scale and share this solution to grow its positive impact. It's amazing to know what we built to help our own hospital is helping others in the same way."

Today, the platform helps more than 30 health systems manage over $8 billion in annual hospital pharmacy spend. To support its rapid growth, QuicksortRx recently moved to a larger corporate headquarters in Charleston, South Carolina. The company has plans to add more than 40 new team members over the next three years to help further scale services and maintain QuicksortRx's high-touch customer support.

"These savings would not have been possible without our amazing team and incredible clients," says Hebbard. "They are real experts who share our passion for bringing positive change to this industry and for reducing the cost of quality healthcare."

Yantis adds, "One hundred million dollars represents a lot of work within and outside of our team at QuicksortRx. We are incredibly grateful to the people who have trusted and had faith in us along this journey. Thank you to these health systems for rolling up your sleeves with us and putting in the work. This milestone is your accomplishment as well."

IRVING, TX – Vizient, Inc. projects drug price inflation to grow at 3.8% in the latest Pharmacy Market Outlook. Driven in part by specialty pharmacy, including the increasing utilization of weight loss drugs, it is the highest projected increase since July 2019. In addition, the anticipated expansion of gene therapies will increase provider spend even more. View the Pharmacy Market Outlook.

"Many hospitals around the country experienced a challenging 2023, including drug shortages and rising drug costs," said Carina Dolan, associate vice president, clinical oncology, pharmacoeconomics and market insights, Vizient. "Managing pharmacy expenditures and strengthening the supply chain is more important than ever."

Specialty pharmaceuticals, which treat high-cost, complex or chronic conditions such as cancer, infectious-, autoimmune- and pulmonary conditions, make up the majority of the top 15 medications in spend among Vizient pharmacy program participants. With 42 novel specialty drugs approved in 2023 — and 2024 likely to see a record number of approvals — the projected price increase for specialty medications is 4.18%.

What's driving the increase in provider spending?

• Weight loss drugs: Spending and utilization of glucagon-like peptide receptor 1 agonists (GLP-1s), which treat type 2 diabetes and obesity, have increased dramatically over the past few years. Semaglutide, a GLP-1 agonist, has risen to the No. 5 spot in total Vizient customer spend, making its way up from No.18 a year ago.
  
  Competitors in this space are making strides to gain market share, including the new indication for tirzepatide (Zepbound™) for weight loss, launched in the U.S. in December 2023. In its most recent annual Impact of Change Forecast, Sg2, a Vizient company, forecasts a 4% reduction in bariatric surgery volumes by 2033 due to anti-obesity medication use.
   
• Gene therapy: One dose of gene therapy, a rapidly growing field that involves modifying the expression of genes for therapeutic purposes, can exceed $2 million. There are currently 11 approved gene therapy products (excluding chimeric antigen receptor (CAR)-T therapies).  
  
  Vizient is tracking more than 170 gene and cellular therapies in the pipeline and expects they will have a significant impact on disease prevention and treatment in the coming years. However, their novelty presents challenges, including cost, proper coding for reimbursement and ultra-low-temperature storage requirements.

Biosimilars expected to grow in market share

Biosimilars made up 24.93% of purchasing volume for originator products and their corresponding biosimilars and are expected to increase in price by only 0.55%. While Humira® still represented 99% of Vizient customer adalimumab purchases through September 2023, biosimilar adalimumab products are expected to gain market share throughout 2024 as pharmacy benefit managers finalize their formulary strategy. However, Humira may continue to be a top spend until biosimilars are mandated at the payer level.

Remdesivir continues to drop

Remdesivir, an anti-viral agent used in the treatment of COVID-19, which first appeared on the top of the Vizient customer spend list in the summer 2021 Outlook, has finally dropped out of the Vizient overall top 15 medications. It remains the top spend agent in the acute care segment of the market.

Projections for this edition of Pharmacy Market Outlook are based on total Vizient Pharmacy program participant spend from October 2022 through September 2023. Price change estimates are projected for July 1, 2024 through June 30, 2025. Read more about the Pharmacy Market Outlook.

STOUGHTON, MA & SAN DIEGO, CA - Shields Health Solutions (Shields), the premier specialty pharmacy accelerator in the country, announced today that it has partnered with Sharp HealthCare (Sharp), a not-for-profit regional healthcare group in San Diego, to collaborate on an expansion of a specialty pharmacy program that provides patients with complex, chronic conditions access to specialized pharmacy services designed to lower costs, expand treatment options, enhance medication management, and improve overall health.

The partnership between Sharp and Shields will offer support services for the unique needs of patients with an initial focus on four key disease states: hematology, oncology, rheumatology, and cardiology. Patients filling their prescriptions at Sharp Specialty Pharmacy Services will receive personalized, patient-centered care complete with side effects management, increased adherence, regular follow-ups, access to financial assistance, and medication delivery at no charge.

"Our new partnership with Sharp HealthCare reaffirms the health system’s unwavering commitment to providing superior patient care," said Stephen West, Chief Executive Officer. "As a Shields partner, Sharp will improve its therapy management and care coordination by securing access to 90 percent of the limited distribution drugs that complex patients need. Our work together will also open restricted payer networks and elevate access to affordable care for Sharp patients."

Sharp HealthCare, San Diego County’s most comprehensive health care delivery system, serves a broad patient population across its system, which includes four acute-care hospitals, three specialty hospitals, three affiliated medical groups, and a full spectrum of facilities and services. The health system consists of 2,700 affiliated physicians and 19,000 employees.

"Our partnership with Shields specifically supports Sharp Specialty Pharmacy’s goal to enhance and grow this vital pharmacy service for Sharp HealthCare’s patients," said Suzanne Shea, vice president of System Pharmacy and Clinical Nutrition at Sharp HealthCare. "This focused support allows our pharmacy team to expand care for Sharp patients and extend our high-quality services throughout the patients’ health care journey."

SCHAUMBURG, IL – Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Bivalirudin for Injection in the United States as a therapeutic equivalent generic for Angiomax^® for Injection (bivalirudin) approved by the U.S. Food and Drug Administration. Bivalirudin for Injection is indicated for use as an anticoagulant for use in patients undergoing percutaneous coronary intervention (PCI) including patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome.

Avenacy’s injectable product contains 250 mg of bivalirudin as a lyophilized powder in a single-dose vial for reconstitution. In line with Avenacy’s mission to champion patient safety and streamline patient care, Bivalirudin for Injection will feature the Company’s highly differentiated packaging and labeling to support accurate medication selection.

Avenacy will begin shipping Bivalirudin for Injection to wholesale partners this week. The Company is supported by a global network of development and FDA-approved cGMP-certified contract manufacturing partners.

Bivalirudin for Injection had U.S. sales of approximately $25 million for the twelve months ending in June 2023.¹

Please see link for Full Prescribing Information.

Angiomax^® is a registered trademark of Sandoz, Inc.

TAMPA, FL - Marking a significant milestone in the TampaWell initiative, Tampa General and the City of Tampa officially welcomed residents to enjoy the benefits of healthy eating with support from a brand-new community garden and food pharmacy. John Couris, president and CEO of Tampa General, and Tampa Mayor Jane Castor were joined by community leaders and area residents to cut the ribbon on the new TampaWell Community Garden and Food Pharmacy, both conveniently located at TGH Family Care Center Healthpark, which serves one of the most food insecure neighborhoods in the region.

"We're on a mission to transform the health and wellness of our community. Healthy foods and regular physical activity play a pivotal role in both the prevention and the treatment of chronic health conditions, but not everyone has access to these essentials," said Couris. "With this new community garden and food pharmacy, we're working to ensure that residents of this community can benefit from nutritious foods, contributing to better health and a greater quality of life."

TampaWell was activated by Tampa General Hospital in 2022, in partnership with the City of Tampa. It was the start of a wellness revolution in Tampa Bay with the goal of making Tampa the ultimate wellness destination in the United States. TampaWell embodies the mission of TGH to empower communities and transform lives, focusing on preventive health care efforts that are proven to reduce chronic disease and hospital readmissions. It also supports the city's most at-risk residents by addressing underlying social factors that impact health.

"Today it's clear that TampaWell is more than a vision for our city, it is a reality. With the new community garden and food pharmacy, we are effectively increasing access to fresh and nutritious foods in areas where we can have the most meaningful impact," said Mayor Castor. "We are grateful to Tampa General and our partners in the community for making these transformations possible."

The TampaWell Food Pharmacy and Community Garden is built on the concept that "food is medicine." With fresh fruits and vegetables grown in the adjacent community garden, patients have greater access to nutritious foods and the opportunity to learn how to grow healthy produce in a sustainable way. Patients at the TGH Family Care Center Healthpark who are diagnosed with prediabetes, diabetes, hypertension or obesity may request a referral from their primary care providers to select nutrient-rich foods from the food pharmacy, free of charge.

"With this community garden and food pharmacy, we can do more than treat patients for their symptoms. We're working to change behavior and help establish new lifestyle routines that can potentially reduce and reverse chronic health conditions," said Adam Smith, executive vice president and chief ambulatory care officer at Tampa General Hospital. "With greater access to nutritious foods, our patients can more effectively improve their overall health."

The TampaWell Food Pharmacy and Community Garden is made possible with the collaboration and support of community partners, including the Feeding Tampa Bay Food Rx Program and the Tampa YMCA Veggie Van Produce Prescription Program. Eligible patients will also have the opportunity to participate in the Tampa YMCA's evidence-based health initiatives, Diabetes Prevention Program or Blood Pressure Self-Monitoring, as appropriate, as well as community-based nutrition and healthy eating classes.

The Food Pharmacy and Community Garden is just one of the many programs offered by TampaWell to connect residents in the region with resources for health and wellness. The TampaWell smartphone app, launched in 2023, is a free resource through which residents can explore wellness events and activities across Tampa Bay, access tips for a healthier life and find motivation to reach goals. In addition, the app tracks physical activity and monitors community-wide progress.

The TampaWell initiative is modeled after the Wellness Valley, an internationally acclaimed effort in the Romagna region of Italy that describes itself as "the first worldwide district of wellness and quality of life" in existence. Wellness Valley draws on some 250 public and private stakeholders in the region to support and amplify its mission of focusing on preventive health rather than the treatment of chronic disease.

TampaWell is a collaboration of more than 80 local organizations, including community groups, businesses, social services agencies and health care providers. While Tampa already has a good foundation for promoting wellness – including a young and growing workforce, a good economic environment, and a solid infrastructure of fitness facilities and programs – data reveals that many area residents can benefit from greater access to health and wellness resources. Roughly 29% of adults in the city are sedentary, about 27% are obese, and 36% have hypertension. TampaWell, together with its partners in the community, is working to address the gaps and improve access to essential services and programs. The goal is to create a culture of sustainable wellness and improve the overall health of the community.

The TampaWell Community Garden and Food Pharmacy is next to the TGH Family Care Center Healthpark, located at 5802 North 30th Street, Tampa, Florida.

TARRYTOWN, NY - The U.S. Food and Drug Administration (FDA) has approved Dupixent^® (dupilumab) for the treatment of pediatric patients aged 1 to 11 years, weighing at least 15 kg, with eosinophilic esophagitis (EoE). Dupixent is now the first and only medicine approved in the U.S. specifically indicated to treat these patients. This approval expands the initial FDA approval for EoE in May 2022 for patients aged 12 years and older, weighing at least 40 kg. The FDA evaluated Dupixent for this expanded indication under Priority Review, which is reserved for medicines that represent potentially significant improvements in efficacy or safety in treating serious conditions.

EoE is a chronic, progressive disease driven in part by type 2 inflammation that damages the esophagus and impairs its function. EoE can severely impact a child’s ability to eat, and they may experience heartburn, vomiting, abdominal discomfort, trouble swallowing, food refusal and failure to thrive. These symptoms can adversely impact their growth and development. Continuous treatment of EoE may be needed to reduce the risk of complications and disease progression. Approximately 21,000 children under the age of 12 in the U.S. are currently being treated for EoE with unapproved therapies. However, the actual prevalence of children with the disease is likely higher, given symptoms can be mistaken for other conditions and there are delays in diagnosis.

Naimish Patel, M.D. - Head of Global Development, Immunology and Inflammation at Sanofi
“Young children with eosinophilic esophagitis have significant unmet medical needs; despite existing treatment options, 40% of these children in the U.S. under the age of 12 continue to experience symptoms of this disease. Today’s approval underscores our commitment to bringing therapies to young patients with unmet needs and also brings hope to these patients who are at a critical age where struggling to eat and maintain weight directly impacts their overall nutritional intake and development.”

The FDA approval is based on data from the Phase 3 EoE KIDS trial with two parts (Part A and Part B) evaluating the efficacy and safety of Dupixent in children aged 1 to 11 years with EoE. At 16 weeks, 66% of children who received higher dose Dupixent at tiered dosing regimens based on weight (n=32) achieved histological disease remission (≤6 eosinophils/high power field), the primary endpoint, compared to 3% for placebo (n=29). Histological remission was sustained at week 52, with 17 of 32 (53%) children treated with Dupixent in Parts A and B. Histological remission was also achieved at week 52 in 8 of 15 (53%) children who switched to Dupixent from placebo in Part B. In addition, a greater decrease in the proportion of days with one or more signs of EoE based on Pediatric EoE Sign/Symptom Questionnaire-caregiver version (PESQ-C) was observed in children treated with Dupixent at 16 weeks compared to placebo. 

George D. Yancopoulos, M.D., Ph.D. - Board co-chair, President and Chief Scientific Officer at Regeneron

“Young children are some of the most vulnerable patients with eosinophilic esophagitis, or EoE, as this debilitating and progressive disease threatens their basic ability to eat. Until today, these children had no approved treatment options specifically for EoE, leaving many with unapproved medicines that failed to target the root cause of their disease. With this approval, Dupixent becomes the first and only treatment option for EoE patients aged 1 year and older, weighing at least 15 kg. By targeting the underlying type 2 inflammation that contributes to this disease, Dupixent has the potential to transform the standard of care for these children as it has for adults and adolescents with EoE.”

The safety profile of Dupixent observed through 16 weeks in children aged 1 to 11 years weighing at least 15 kg was generally similar to the safety profile of Dupixent observed through 24 weeks in adult and pediatric patients aged 12 years and older with EoE. The most common adverse events (≥2%) more frequently observed with Dupixent than placebo were injection site reactions, upper respiratory tract infections, arthralgia (joint pain) and herpes viral infections. In EoE KIDS Part B, one case of helminth infection was reported in the Dupixent arm.

IRVING, TX - The End Drug Shortages Alliance (EDSA) announces the appointment of Terri Lyle Wilson, vice president of pharmacy for The Children’s Hospital Association, as its new chair. Wilson succeeds past-board chair Eric Tichy, PharmD, MBA, FCCP, division chair, pharmacy supply solutions, Mayo Clinic.

Tichy helped launch the End Drug Shortages Alliance in 2021 and was appointed chair in December 2021. Under his leadership, EDSA has grown to a non-profit organization of 80 member organizations with more than 255 active participants, including representatives from healthcare providers, pharmaceutical manufacturers, suppliers, distributors, group purchasing organizations and other thought leaders.

During Tichy’s tenure as board chair, EDSA responded to market supply disruptions with expert analysis and drug shortage mitigation strategies, including:

Wilson, who's been involved with EDSA since its beginning, brings a wealth of knowledge and experience to her new role. As the vice president of pharmacy for Children's Hospital Association, Wilson is a proven leader in the pharmacy industry, advocating for improved patient care and access to medication.

"I am very grateful to Eric for his leadership and am honored to step into the role of board chair for the End Drug Shortages Alliance," said Wilson. "I look forward to working with this dedicated group of individuals to continue our efforts in addressing and mitigating drug shortages for the betterment of patient care for children and adults."

Wilson will lead EDSA in its five-year strategy that will include developing drug shortage communication standards across the industry; executing a centralization strategy for communication of drug shortages to all industry stakeholders; and establishing and publishing guidance on inventory management best practices.

EDSA also welcomes its newly appointed chair-elect Jason Chou, vice president pharmacy services, Ochsner Health and Jessica Daley, group vice president, supply chain, Premier, Inc. as treasurer.

About End Drug Shortages Alliance

The End Drug Shortages Alliance is a collaboration of healthcare industry stakeholders, including providers, group purchasing organizations, manufacturers, distributors and other industry thought leaders dedicated to solving the pharmaceutical supply challenges that disrupt access to essential medications in the U.S. We prioritize initiatives focused on transparency, quality, redundancy and production of additional supply to achieve undisrupted access to essential medications for healthcare providers and patients.

PARIS - Sanofi and Inhibrx, Inc. (“Inhibrx”), a publicly traded clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates, have entered into a definitive agreement under which Sanofi has agreed to acquire Inhibrx following the spin-off of non-INBRX-101 assets into New Inhibrx. INBRX-101 is a human recombinant protein that holds the promise of allowing Alpha-1 Antitrypsin Deficiency (AATD) patients to achieve normalization of serum AAT levels with less frequent (monthly vs. weekly) dosing. AATD is an inherited rare disease characterized by low levels of AAT protein, predominantly affecting the lung with progressive deterioration of the tissue. INBRX-101 may help to reduce inflammation and prevent further deterioration of lung function in affected individuals.

Houman Ashrafian  
Head of Research and Development, Sanofi 
“The addition of INBRX-101 as a high potential asset to our rare disease portfolio reinforces our strategy to commit to differentiated and potential best-in-class products. With our expertise in rare diseases and growing presence in immune-mediated respiratory conditions, INBRX-101 will complement our approach to deploy R&D efforts in key areas of focus and address the needs of the underserved AATD patients and communities.”

INBRX-101 has successfully completed a Phase 1 trial, demonstrating positive results in terms of safety and pharmacokinetics and is currently enrolling a Phase 2 clinical trial to further evaluate the potential of INBRX-101 as a treatment for AATD. If successful, INBRX-101 could offer a significant improvement in the treatment options and quality of life for AATD patients.

Transaction Terms

Under the terms of the merger agreement, Sanofi and Inhibrx have agreed to the following:

• Sanofi will acquire all outstanding shares of Inhibrx for $30.0 per share in cash, representing an equity value of approximately $1.7 billion (on a fully diluted basis);
• Inhibrx’s shareholders will receive one non-transferable CVR per Inhibrx share, which will entitle its holder to receive a deferred cash payment of $5.0, conditioned upon the achievement of a regulatory milestone. Assuming the conditions of the CVR are met, this would represent additional cash consideration of approximately $296 million for Inhibrx’s shareholders;
• Sanofi will be responsible for the satisfaction of Inhibrx’s currently outstanding third-party debt;
• Inhibrx’s shareholders will receive 0.25 shares of the newly created entity New Inhibrx per Inhibrx share. New Inhibrx will be capitalized with $200 million of cash at distribution; 
• Sanofi will retain an 8% equity stake in New Inhibrx.

New Inhibrx will retain non-INBRX-101 assets, notably including its immuno-oncology pipeline (INBRX-109, INBRX-106, INBRX-105), as well as Inhibrx assets not related to INBRX-101 and Inhibrx’s employees. It will be led by Mark P. Lappe, Founder and CEO of Inhibrx, as Chairman and CEO of New Inhibrx, and will continue to operate under the Inhibrx name. 

The transaction was unanimously approved by both the Sanofi and Inhibrx Boards of Directors.

Sanofi’s acquisition of Inhibrx is subject to the completion of the New Inhibrx spin-off transaction and other customary closing conditions, including receipt of regulatory approvals and approval by Inhibrx’s shareholders. The companies expect the transaction to close in the course of Q2 2024.

Sanofi expects to finance the transaction with available cash resources.

Lazard is acting as exclusive financial advisor to Sanofi and Weil, Gotshal & Manges LLP is acting as its legal counsel. Centerview Partners LLC is acting as exclusive financial advisor to Inhibrx and Paul, Weiss, Rifkind, Wharton and Garrison LLP is serving as legal counsel.

IRVINE, CA - Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the results of a consumer survey designed to examine the value proposition of Allē, Allergan Aesthetics loyalty rewards program. The survey of Allē Members who have been treated in the past twelve months affirmed Allē's position as the leading aesthetics loyalty rewards program in the country, with a ninety-two percent satisfaction rate reported by survey respondents^1*.

In serving more than six million Members across 19,000 practices to-date, part of Allē's mission is to help educate consumers about aesthetic treatments such as BOTOX^® Cosmetic (onabotulinumtoxinA), the JUVÉDERM^® Collection of Fillers, SKINVIVE by JUVÉDERM^®, CoolSculpting^®, SkinMedica^®, DiamondGlow^®, and more. From its inception, Allē has disrupted the aesthetics industry by offering the most robust rewards program in the category. By providing its Members with information, tools, and incentives, Allē empowers consumers along their treatment journey, making their next product purchase or treatment closer within reach.

Key Allē features and attributes that keep Allē Members satisfied and engaged include:

• Cost Savings: The survey found that the primary motivation for becoming an Allē Member was wanting to use an offer to save money on a treatment¹.
• Earn Points, Even on Non-Allē Treatments: Allergan Aesthetics recognizes that people deserve to be rewarded, no matter their treatment regimens. That's why Allē is the first and only aesthetics loyalty rewards program to give its users points on more than 40 brands, products, and treatments at their Allē provider—even those that are not Allē brands.
• Treatment Education: With original content and information across the app, Allē serves as a partner for discovery to help Members learn about other treatments. In fact, 77% of respondents reported that they found Allē extremely or very valuable in helping them decide what aesthetics brands to ask their provider about ahead of treatment¹. That, coupled with more than one million patients reading an Allē article prior to their first treatment, has made the program an invaluable resource to help guide them on their treatment journeys.
• Exclusive Rewards: Allē Members who accrue 1,200 points within a calendar year can unlock an exclusive, VIP membership called "The A List" that gives them added membership benefits like: points that never expire as long as you're on The A List, the A Line VIP Member support, surprise gifts, and early access to offers and events.

"With so many aesthetics loyalty rewards programs available, our commitment to continuing to drive value is what keeps us as the preferred platform among consumers and providers," said Jasson W. Gilmore, Senior Vice President, Allergan Data Labs at Allergan Aesthetics. "The value Allē delivers to our customers is twofold: first, we provide consumers with a curated aesthetic experience that is tailored to their individual needs and aesthetic goals. Second, we streamline the provider experience, from creating a seamless in-office experience (like booking an appointment or checking out) and providing insights about consumer treatment behaviors and trends, to helping them retain and attract patients into their practice."

"Allē for Business, the provider component of Allē, has truly become one of our most trusted in-office tools to acquire and retain aesthetics patients in our practice," said Kathleen Morno M.D., Board Certified Ophthalmologist and Facial Aesthetics Specialist at RL Center for Cosmetic Surgery & Medspa. "From the promotional elements that encourage patients to book an appointment to the patient trends and data that Allē provides to help me offer patients more customized treatment plans, we have seamlessly, and easily, integrated Allē into every touchpoint of our patient experience. With Allē, I can better provide my patients a curated experience that is tailored to their aesthetic goals and helps keep them coming back."

For consumers interested in participating, please visit www.alle.com to join and start taking advantage of exclusive offers and access. For providers looking to engage with Allē for Business, please contact your local Allergan Aesthetics Business Development Manager.

*In an online survey, 92% (n = 737) of patients reported they were "Very Satisfied" or "Satisfied" (top 2 out of 5 responses) with their Allē experience.

PRINCETON, NJ - Bristol Myers Squibb (NYSE: BMY) today announced that it has successfully completed its acquisition of Mirati Therapeutics, Inc.^® (“Mirati”). With the completion of the acquisition, Mirati shares have ceased trading on the NASDAQ Global Select Market and Mirati is now a wholly owned subsidiary of Bristol Myers Squibb.

“The closing of the Mirati transaction is a significant milestone in our efforts to further diversify our oncology portfolio and strengthen our pipeline in the latter half of the decade and beyond,” said Chris Boerner, Ph.D., Chief Executive Officer, Bristol Myers Squibb. “Mirati’s incredibly talented employees have built a strong portfolio of assets and capabilities that are highly complementary with BMS’. We welcome them and look forward to working together to leverage BMS’ global scale and resources to deliver more treatments for cancer patients, faster.”

Through this transaction, BMS has added commercialized lung cancer medicine KRAZATI (adagrasib) to its oncology portfolio as well as several promising clinical assets, including a potential first-in-class MTA-cooperative PRMT5 inhibitor in Phase 1 development, and a leading KRAS and KRAS enabling program with two candidates in Phase 1 development.

The transaction is expected to be treated as a business combination and to be dilutive to Bristol Myers Squibb’s non-GAAP earnings per share by approximately $0.35 per share in 2024.